We are delighted to announce that Eagle IP has been recognized once more by IAM Patent 1000 - The World's Leading Patent Professionals - as a top ranked, “Highly Recommended Firm in Patent Prosecution”.

The IAM Patent 1000 is a respected annual directory dedicated to identifying leading patent firms and individual practitioners globally. Published by Intellectual Asset Management (IAM), the guide covers key jurisdictions and evaluates capabilities across the core areas of patent law. Inclusion in the directory is determined by a rigorous, independent research process that includes 900+ extensive interviews with in-house counsel, patent attorneys, and industry experts.

According to IAM, Eagle IP has carved out “a distinctive reputation for far-reaching and highly sophisticated patent protection” and “a prime pick for life sciences companies, research institutions and technology-driven enterprises navigating complex international patent strategies.”

IAM has further highlighted five individuals from our firm: Our President and Managing Director, Ms. Jennifer Che, Principal Ms. Yolanda Wang, Principal Ms. Pauli Wong, Dr. Jacqueline C Lui, Dr. Ho Chung Lui.

We are incredibly honoured to be included in this highest category among a select group of Hong Kong’s top IP firms. We are deeply grateful to IAM for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US, Chinese, and Hong Kong patent laws, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我們過去活動

Recommended Insights

Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

Chinese Courts Cares More About Patent Quality Now (A Doctrine of Equivalents Story)

2022年12月13日
There is no doubt that the drafting quality of a patent can be crucial in determining the success (or failure!) of the patent during litigation. However, due to various reasons, patents often fail to use the right drafting strategies that best protect the invention. Too often, inexperienced or unsophisticated patent drafters merely listen to an […]

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

2018年11月23日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

China Finally Clamps Down on Facial Recognition Technology

2021年8月24日
Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Around the end of July 2021, the Supreme People’s Court issued a new Provision concerning the application of law about a super-hot technology, facial recognition. This Provision is a legal explanation from the SPC explaining how the law should be applied or interpreted […]
Top crossarrow-right